In modern medicine, the Sansure S3057E HPV 13+2 – Human Papillomavirus DNA Diagnostic Kit stands out as a beacon of hope in the fight against cervical carcinoma. This reliable kit, designed for PCR-Fluorescence Probing, targets 13 high-risk genotypes and two medium-risk genotypes, HPV 53 and 66, ensuring comprehensive screening and risk evaluation capabilities.
Unveiling the Power of Human Papillomavirus DNA Diagnostic Kit
The Human Papillomavirus DNA Diagnostic Kit (PCR-Fluorescence Probing) chooses the above 13 high-risk genotypes and two popular medium-risk genotypes to be the target genotypes. This strategic selection guarantees that the kit is not only capable of cervical carcinoma screening but also excels at risk assessment, empowering healthcare professionals with invaluable insights into patient health.
Understanding the Significance of Genotype Classification
Based on the study results by WHO International Agency for Research on Cancer (IARC) and other international organizations, the 13 high-risk genotypes including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, are classified as high-risk HPV. Additionally, the 5 medium-risk genotypes including HPV26, 53, 66, 73, 82, are identified as medium-risk HPV. This meticulous categorization ensures that the Sansure S3057E HPV 13+2 kit provides accurate and reliable results for healthcare providers and patients alike.
Conclusion
In conclusion, the Sansure S3057E HPV 13+2 – Human Papillomavirus DNA Diagnostic Kit emerges as a game-changer in cervical carcinoma screening. By leveraging advanced technology and targeting specific high and medium-risk genotypes, this kit not only simplifies the testing process but also enhances the efficiency and accuracy of HPV testing. Embrace the future of healthcare with the Sansure HPV test kit and prioritize early detection for better patient outcomes.